An evolving understanding of the immunopathogenesis of multiple sclerosis suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a humanized monoclonal antibody that ...
Two decades of clinical experience with the immunomodulatory treatment of multiple sclerosis points to distinct immunological pathways that drive disease relapses and progression. Although the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback